title: Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
abstract: We have tested the predictive value of apparent diffusion coefficient (ADC) histogram analysis in stratifying progression-free survival (PFS) and overall survival (OS) in bevacizumab-treated patients with recurrent glioblastoma multiforme (GBM) from the multi-center BRAIN study. Available MRI's from patients enrolled in the BRAIN study (n = 97) were examined by generating ADC histograms from areas of enhancing tumor on T1 weighted post-contrast images fitted to a two normal distribution mixture curve. ADC classifiers including the mean ADC from the lower curve (ADC-L) and the mean lower curve proportion (LCP) were tested for their ability to stratify PFS and OS by using Cox proportional hazard ratios and the Kaplan-Meier method with log-rank test. Mean ADC-L was 1,209 × 10(-6)mm(2)/s ± 224 (SD), and mean LCP was 0.71 ± 0.23 (SD). Low ADC-L was associated with worse outcome. The hazard ratios for 6-month PFS, overall PFS, and OS in patients with less versus greater than mean ADC-L were 3.1 (95 % confidence interval: 1.6, 6.1; P = 0.001), 2.3 (95 % CI: 1.3, 4.0; P = 0.002), and 2.4 (95 % CI: 1.4, 4.2; P = 0.002), respectively. In patients with ADC-L <1,209 and LCP >0.71 versus ADC-L >1,209 and LCP <0.71, there was a 2.28-fold reduction in the median time to progression, and a 1.42-fold decrease in the median OS. The predictive value of ADC histogram analysis, in which low ADC-L was associated with poor outcome, was confirmed in bevacizumab-treated patients with recurrent GBM in a post hoc analysis from the multi-center (BRAIN) study.
authors.affiliation: Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1721, USA. wpope@mednet.ucla.edu
authors.forename: Whitney B
authors.initials: WB
authors.lastname: Pope
authors.forename: Xin Joe
authors.initials: XJ
authors.lastname: Qiao
authors.forename: Hyun J
authors.initials: HJ
authors.lastname: Kim
authors.forename: Albert
authors.initials: A
authors.lastname: Lai
authors.forename: Phioanh
authors.initials: P
authors.lastname: Nghiemphu
authors.forename: Xi
authors.initials: X
authors.lastname: Xue
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Ellingson
authors.forename: David
authors.initials: D
authors.lastname: Schiff
authors.forename: Dawit
authors.initials: D
authors.lastname: Aregawi
authors.forename: Soonmee
authors.initials: S
authors.lastname: Cha
authors.forename: Vinay K
authors.initials: VK
authors.lastname: Puduvalli
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.forename: Wai-Kwan A
authors.initials: WK
authors.lastname: Yung
authors.forename: Geoffrey S
authors.initials: GS
authors.lastname: Young
authors.forename: James
authors.initials: J
authors.lastname: Vredenburgh
authors.forename: Dan
authors.initials: D
authors.lastname: Barboriak
authors.forename: Lauren E
authors.initials: LE
authors.lastname: Abrey
authors.forename: Tom
authors.initials: T
authors.lastname: Mikkelsen
authors.forename: Rajan
authors.initials: R
authors.lastname: Jain
authors.forename: Nina A
authors.initials: NA
authors.lastname: Paleologos
authors.forename: Patricia
authors.initials: P
authors.lastname: Lada
authors.forename: Michael
authors.initials: M
authors.lastname: Prados
authors.forename: Jonathan
authors.initials: J
authors.lastname: Goldin
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Timothy
authors.initials: T
authors.lastname: Cloughesy
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D005909:Glioblastoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control*; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab